Utilizing circulation-derived cancer cells to evaluate patients with surgically treated stages I–IIIA NSCLC throughout the preoperative phase


Year : 2024 | Volume : 13 | Issue : 03 | Page : 17-28
    By

    Tshetiz Dahal,

  • Ankit Singh,

  1. General Physician, Clinical Researcher, Lugansk State Medical University, Lypnia, Ukraine
  2. Researcher, Department of Pharmacy Lloyd Institute of Technology and Management, Uttar Pradesh, India

Abstract

Context: When a tumor is considered resectable, surgery is viewed as the primary treatment approach for both early-stage and locally advanced non-small cell lung cancer (NSCLC). One of the most exciting areas of cancer research in the past ten years is liquid biopsy, which offers a practical non-invasive method for cancer detection and tracking. Circulating tumor cells (CTCs) have been linked to a worse prognosis and increased chance of relapse in various cancer types where their prognostic significance has been examined. This study aims to assess the predictive significance of CTC identification in surgically treated patients with stage I–IIIA NSCLC. Methodology: We included 180 consecutive patients with resected, pathologically confirmed stage I to IIIA NSCLC (according to the TNM AJCC/UICC 8th edition) in our prospective, single-center study. Prior to and following surgery, the blood samples from the patients were processed, and CTCs were described. Following chemotherapy and surgery, a patient cohort had their CTC determined. Cut-off thresholds were set for statistical analysis in CTCs 1 and 5. Result: Before surgery, 76.7% of the patients had at least one circulating tumor cell (CTC), and 30.6% had five or more. After surgery, 55.9% still had at least one CTC, while 8.3% had five or more. Preoperative CTC detection with a cut-off of 5 did not correlate with any of the following outcomes: relapse (32.7% vs. 28.8%, P=0.596), disease-free survival (DFS) (HR: 0.95, P=0.39), or overall survival (OS) [hazard ratio (HR): 0.99, P=0.887]. Additionally, at a cut-off of 5, we did not observe any link between the detection of postoperative CTCs and OS (HR: 1.01, P=0.808), DFS (HR: 0.95, P=0.952), or relapse (26.7% vs. 29.5%, P=0.83). The average change in the number of CTCs from before to after surgery was 2.13, with a standard deviation of 6.78. Conclusion: CTC monitoring in the perioperative period was not connected with recurrence, DFS, or OS in our investigation, despite the sizeable patient cohort included. As a result, it cannot be suggested as a trustworthy biomarker for minimal residual disease (MRD) following surgery.

Keywords: Non-small cell lung cancer (NSCLC), circulation, circulating tumor cell (CTC), liquid biopsy, surgery.

[This article belongs to Research & Reviews : Journal of Surgery ]

How to cite this article:
Tshetiz Dahal, Ankit Singh. Utilizing circulation-derived cancer cells to evaluate patients with surgically treated stages I–IIIA NSCLC throughout the preoperative phase. Research & Reviews : Journal of Surgery. 2024; 13(03):17-28.
How to cite this URL:
Tshetiz Dahal, Ankit Singh. Utilizing circulation-derived cancer cells to evaluate patients with surgically treated stages I–IIIA NSCLC throughout the preoperative phase. Research & Reviews : Journal of Surgery. 2024; 13(03):17-28. Available from: https://journals.stmjournals.com/rrjos/article=2024/view=189455


References

  1. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016;34:611-35.
  2. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv1-21.
  3. Provencio M, Serna-Blasco R, Nadal E, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol 2022;40:2924-33.
  4. Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 2022;386:1973-85.
  5. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 2009; 115:5218-27.
  6. Pérez-Callejo D, Romero A, Provencio M, et al. Liquid biopsy-based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res 2016; 5:455-65.
  7. Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov 2021; 11:858-73.
  8. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224ra24.
  9. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol 2011; 29:1547-55.
  10. Li Z, Xu K, Tartarone A, et al. Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study. Transl Lung Cancer Res 2021; 10:995-1006.
  11. Sawabata N, Nakamura T, Kawaguchi T, et al. Circulating tumor cells detected only after surgery for non-small cell lung cancer: is it a predictor of recurrence? J Thorac Dis 2020; 12:4623-32.
  12. Sawabata N, Funaki S, Hyakutake T, et al. Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood? Surg Today 2016; 46:1402-9.
  13. Wei S, Guo C, He J, et al. Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients with Non-Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis. JAMA Surg 2019;154: e190972.
  14. Provencio M, Torrente M, Calvo V, et al. Prognostic value of quantitative ctDNA levels in non-small cell lung cancer patients. Oncotarget 2017; 9:488-94.
  15. Provencio M, Pérez-Callejo D, Torrente M, et al. Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients. Oncotarget 2017; 8:59408-16.
  16. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67:93-99.
  17. Jacob J, Krell J, Castellano L, et al. Determination of cut-offs for circulating tumor cell measurement in metastatic cancer. Expert Rev Anticancer Ther 2011; 11:1345-50.
  18. Peeters DJ, van Dam PJ, Van den Eynden GG, et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer 2014; 110:375-83.
  19. Müller V, Riethdorf S, Rack B, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012;14: R118.
  20. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011; 29:1556-63.
  21. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23:1420-30.
  22. Giuliano M, Giordano A, Jackson S, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011;13: R67.
  23. Li Y, Cheng X, Chen Z, et al. Circulating tumor cells in peripheral and pulmonary venous blood predict poor long-term survival in resected non-small cell lung cancer patients. Sci Rep 2017; 7:4971.
  24. Bayarri-Lara C, Ortega FG, Cueto Ladrón de Guevara A, et al. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection. PLoS One 2016;11: e0148659.
  25. Crosbie PA, Shah R, Krysiak P, et al. Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. J Thorac Oncol 2016; 11:1793-7.
  26. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011; 17:827-35.
  27. de Miguel-Pérez D, Bayarri-Lara CI, Ortega FG, et al. Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. Cancers (Basel) 2019; 11:1750.
  28. Syrigos K, Fiste O, Charpidou A, et al. Circulating tumor cells count as a predictor of survival in lung cancer. Crit Rev Oncol Hematol 2018; 125:60-8.
  29. Coco S, Alama A, Vanni I, et al. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Int J Mol Sci 2017; 18:1035.
  30. Juan O, Vidal J, Gisbert R, et al. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine. Clin Transl Oncol 2014; 16:637-43.
  31. Hirose T, Murata Y, Oki Y, et al. Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res 2012; 20:131-7.
  32. Chinniah C, Aguarin L, Cheng P, et al. Early Detection of Recurrence in Patients with Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis. Clin Lung Cancer 2019; 20:384-390.e2.
  33. Frick MA, Feigenberg SJ, Jean-Baptiste SR, et al. Circulating Tumor Cells Are Associated with Recurrent Disease in Patients with Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy. Clin Cancer Res 2020; 26:2372-80.
  34. Xie Z, Gao X, Cheng K, et al. Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period. Oncol Lett 2017; 14:5825-30.
  35. Wan L, Liu Q, Liang D, et al. Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis. Front Oncol 2021; 11:630672.
  36. Yang Y, Xie X, Wang Y, et al. A systematic review and meta-analysis of the influence of STAS on the long-term prognosis of stage I lung adenocarcinoma. Transl Cancer Res 2021; 10:2428-36.
Regular Issue Subscription Original Research
Volume 13
Issue 03
Received 21/08/2024
Accepted 19/10/2024
Published 18/11/2024
Total Visits: 83


Loading citations…